FDA Approved: OZURDEX — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Ozurdex (dexamethasone) by Allergan, authorizing an expanded indication for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Edema Following Retinal Vein Occlusion
• Noninfectious Posterior Uveitis

Drugs mentioned

• Ozurdex (dexamethasone intravitreal implant)

Snippet

SUPPL AP for OZURDEX (DEXAMETHASONE)